WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 318875
Description: Tinidazole is an antiprotozoal, antibacterial agent. The nitro- group of tinidazole is reduced by cell extracts of Trichomonas. The free nitro- radical generated as a result of this reduction may be responsible for the antiprotozoal activity. Chemically reduced tinidazole was shown to release nitrites and cause damage to purified bacterial DNA in vitro. Additionally, the drug caused DNA base changes in bacterial cells and DNA strand breakage in mammalian cells. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.
MedKoo Cat#: 318875
Chemical Formula: C8H13N3O4S
Exact Mass: 247.06268
Molecular Weight: 247.269
Elemental Analysis: C, 38.86; H, 5.30; N, 16.99; O, 25.88; S, 12.97
Synonym: Tinidazole; Bioshik; CP 12,574; CP 12574; CP-12,574; CP-12574; CP12,574; CP12574; Farmasierra; Fasigin; Fasigyn; Fasigyne; Fasygin; Simplotan; Teofarma; Tinidazole; Tricolam
IUPAC/Chemical Name: 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
InChi Key: HJLSLZFTEKNLFI-UHFFFAOYSA-N
InChi Code: InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
SMILES Code: O=[N+](C1=CN=C(C)N1CCS(=O)(CC)=O)[O-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 247.269 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Escobedo AA, Ballesteros J, González-Fraile E, Almirall P. A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children. Acta Trop. 2016 Jan;153:120-7. doi: 10.1016/j.actatropica.2015.09.023. Epub 2015 Oct 22. Review. PubMed PMID: 26476393.
2: Granizo JJ, Pía Rodicio M, Manso FJ, Giménez MJ. [Tinidazole: a classical anaerobical drug with multiple potential uses nowadays]. Rev Esp Quimioter. 2009 Jun;22(2):106-14. Review. Spanish. PubMed PMID: 19544102.
3: Manso F, Gamboa MS, Giménez M, Bascones A, Gómez-Lus ML, Aguilar L. [Why not revisiting tinidazole as potential treatment of odontogenic infections?]. Rev Esp Quimioter. 2008 Sep;21(3):198-202. Review. Spanish. PubMed PMID: 18791873.
4: Sud B, Salvaggio M, Greenfield R, Bronze MS. Part XI. Trimethoprim-sulfamethoxazole, nitrofurantoin, chloramphenicol, metronidazole and tinidazole, rifaximin, and nitazoxanide. J Okla State Med Assoc. 2007 Jul;100(7):267-72. Review. Erratum in: J Okla State Med Assoc. 2007 Oct;100(10):405. Greenfield, Ronald A [corrected to Greenfield, Ronald]. PubMed PMID: 17896614.
5: Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis. Med Lett Drugs Ther. 2007 Sep 10;49(1269):73-4. Review. PubMed PMID: 17848905.
6: Nailor MD, Sobel JD. Tinidazole for bacterial vaginosis. Expert Rev Anti Infect Ther. 2007 Jun;5(3):343-8. Review. PubMed PMID: 17547500.
7: Nailor MD, Sobel JD. Tinidazole for the treatment of vaginal infections. Expert Opin Investig Drugs. 2007 May;16(5):743-51. Review. PubMed PMID: 17461745.
8: Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther. 2005 Dec;27(12):1859-84. Review. PubMed PMID: 16507373.
9: Manes G, Balzano A. Tinidazole: from protozoa to Helicobacter pylori--the past, present and future of a nitroimidazole with peculiarities. Expert Rev Anti Infect Ther. 2004 Oct;2(5):695-705. Review. PubMed PMID: 15482233.
10: Nord CE, Kager L. Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections. Infection. 1983 Jan-Feb;11(1):54-60. Review. PubMed PMID: 6341253.
11: Packard RS. Tinidazole: a review of clinical experience in anaerobic infections. J Antimicrob Chemother. 1982 Aug;10 Suppl A:65-78. Review. PubMed PMID: 6749795.
12: Nord CE. Microbiological properties of tinidazole: spectrum, activity and ecological considerations. J Antimicrob Chemother. 1982 Aug;10 Suppl A:35-42. Review. PubMed PMID: 6749794.
13: Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs. 1982 Aug;24(2):85-117. Review. PubMed PMID: 6749473.
14: Noguchi Y, Tanaka T. Aspects of the pharmacology and pharmacokinetics of nitroimidazoles with special reference to tinidazole. Drugs. 1978;15 Suppl 1:10-5. Review. PubMed PMID: 350561.